Contrasting of Applied Therapeutics Inc. (APLT) and Neuralstem Inc. (NASDAQ:CUR) – MS Wkly

Applied Therapeutics Inc. (NASDAQ:APLT) and Neuralstem Inc. (NASDAQ:CUR) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings & Valuation

Table 1 showcases the gross revenue, earnings per share and valuation of Applied Therapeutics Inc. and Neuralstem Inc.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Insider & Institutional Ownership

The shares of both Applied Therapeutics Inc. and Neuralstem Inc. are owned by institutional investors at 0% and 4.9% respectively. On the other hand, insiders owned about 1% of Neuralstem Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Applied Therapeutics Inc. has stronger performance than Neuralstem Inc.

Summary

Applied Therapeutics Inc. beats Neuralstem Inc. on 6 of the 9 factors.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the original post:
Contrasting of Applied Therapeutics Inc. (APLT) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly